Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALDX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
ALDX reported $45.1M in cash and short-term investments (as of Jun 30, 2026) and used about $4.9M/quarter in operations, an estimated runway of 27.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
Based on our current operating plan, and excluding any potential licensing and product revenue, we believe that our cash and cash equivalents as of June 30, 2026, will be sufficient to fund our currently projected operating expenses into the second half 2028, including continued early and late-stage development of our10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALDX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC 10% owner |
Insider | 5,875,851 | 9.74% | 2025-04-03 |
| AQR Capital Management, LLC | Institution (13G, 5%+) | 3,751,558 | 6.22% | 2026-06-30 |
| Todd C Brady President and CEO, Director · +3.32M options |
Insider | 1,721,298 | 2.85% | 2026-06-03 |
| Stephen Machatha Chief Development Officer · +202,427 options |
Insider | 221,799 | 0.37% | 2025-08-11 |
| Richard Douglas Director · +5,227 options |
Insider | 195,000 | 0.32% | 2026-03-19 |
| Bruce Greenberg Interim Chief Financial Officer · +252,280 options |
Insider | 126,382 | 0.21% | 2024-08-12 |
| Michael Alfieri Principal Financial Officer |
Insider | 7,500 | 0.01% | 2026-03-18 |
| Nancy Miller-Rich Director · +7,467 options |
Insider | 922 | 0.00% | 2021-05-03 |
Share count 60,326,421 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-03-17 | reproxalap | NDA | -19.4% | -70.7% | -47.3% |
| 2026-03-16 | Reproxalap | NDA | -22.5% | +2.6% | -56.1% |
| 2025-12-16 | Reproxalap | NDA | -20.5% | +33.1% | +38.9% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALDX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →